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Abstract
Background: Laparoscopic adrenalectomy is still controversial in cases where malignancy is suspected. However,
many proponents of this technique argue that in the hands of an experienced surgeon, laparoscopy can be safely
performed. The aim of this study is to present our own experience with the application of laparoscopic surgery for
the treatment of malignant and potentially malignant adrenal tumours.
Methods: Our analysis included 52 patients who underwent laparoscopic adrenalectomy in 2003–2014 due to a
malignant or potentially malignant adrenal tumour. Inclusion criteria were primary adrenal malignancy, adrenal
metastasis or pheochromocytoma with a PASS score greater than 6. We analyzed the conversion rate, intra- and
postoperative complications, intraoperative blood loss and R0 resection rate. Survival was estimated using the
Kaplan-Meier method.
Results: Conversion was necessary in 5 (9.7 %) cases. Complications occurred in a total of 6 patients (11.5 %).
R0 resection was achieved in 41 (78.8 %) patients and R1 resection in 9 (17.3 %) patients. In 2 (3.9 %) cases R2
resection was performed. The mean follow-up time was 32.9 months. Survival depended on the type of tumour
and was comparable with survival after open adrenalectomy presented in other studies.
Conclusions: We consider that laparoscopic surgery for adrenal malignancy can be an equal alternative to open
surgery and in the hand of an experienced surgeon it guarantees the possibility of noninferiority. Additionally,
starting a procedure with laparoscopy allows for minimally invasive evaluation of peritoneal cavity. The key element
in surgery for any malignancy is not the surgical access itself but the proper technique.
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Background
Laparoscopic adrenalectomy is currently the gold stand-
ard for the surgical treatment of adrenal pathology [1, 2].
Initially, laparoscopy was only applied in the surgery of
small adrenal tumours, the character of which indicated
a benign lesion. Indications for laparoscopy have grad-
ually broadened since it has been established that prac-
tically any tumour, including very large ones, can be
successfully removed with this technique. It has obvi-
ously typical advantages for minimally invasive surgery: a
lower complication rate, less postoperative pain, faster
recovery, a shorter length of hospital stay and a better
cosmetic effect [3, 4, 1, 5]. However, its use is still contro-
versial in cases where malignancy is suspected. One of
the concerns is that maintaining the proper oncological
technique may be more difficult in comparison to open
access, and thus there would be a higher risk of tumour
capsule injury, which leads to intraoperative dissemin-
ation of cancer cells [6]. However, proponents of mi-
nimally invasive techniques argue that in the hands of
an experienced surgeon, laparoscopy can be safely per-
formed while preserving the principles of oncologic
surgery, with results similar to those of open access
[7]. The aim of this study is to present our own
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experience with the application of laparoscopic surgery
in the treatment of malignant and potentially malig-
nant adrenal tumours.
Methods
Our analysis included patients who underwent laparo-
scopic adrenalectomy at our centre in the years 2003–
2014 due to a malignant or potentially malignant adrenal
tumour. The inclusion criterion was a postoperative pa-
thological diagnosis confirming the character of the lesion:
primary malignant tumour of the adrenal gland, pheo-
chromocytoma with a high risk of postoperative malignant
course or isolated adrenal metastasis after radical treat-
ment of a primary lesion. We excluded from the study
patients who were submitted to open surgery or patients
with an inoperable tumour with distant metastases. Pre-
operative staging in all cases was comprised of computed
tomography (CT), magnetic resonance imaging (MRI) or
in selected cases a positron emission tomography (PET)
scan. The criteria for potential malignancy in imaging
studies included: invasion into adjacent organs or vessels,
local or distant lymphadenopathy, increased and heteroge-
neous signal intensity on CT and on T2-weighted MRI,
increased fludeoxyglucose uptake on PET and growth over
time.
Prior to surgery a routine panel of laboratory tests were
carried out to establish the hormonal activity of the
tumour. The evaluation included plasma cortisol, urinary
free cortisol, ACTH, DHEAS, 17-OH-progesterone, tes-
tosterone, plasma renin activity as well as aldosterone,
urinary aldosterone, catecholamines and vanillylmandelic
acid excretion. In the case of suspected pheochromocy-
toma, patients were preoperatively treated with alpha-
blockers (doxazosin 20 mg/day) (additional beta-blockers
in case of co-existing tachycardia) and intravenous volume
expansion with crystalloids and colloids (2000 ml/day
starting on the day before surgery).
We performed laparoscopy using the transperitoneal
lateral approach. The same laparoscopic surgeon (AB)
with extensive expertise in adrenal surgery (more than
370 laparoscopic adrenalectomies) performed all laparo-
scopic transperitoneal lateral adrenalectomies. The first
attempt to use the laparoscopic approach in case of sus-
pected malignancy was after completion of his learning
curve (50 laparoscopic adrenalectomies). The principle
during surgery was to avoid direct manipulating or
applying pressure to the tumour to prevent perforation
of the tumour capsule, or, in the case of pheochromo-
cytomas, secretion of catecholamines. Any suspicion of
damage to the tumour capsule was considered an indica-
tion for conversion. The adrenal gland with the tumour
was resected with a margin of surrounding tissue and
removed in a plastic laparoscopic bag. After surgery,
patients were submitted to adjuvant therapy according
to their primary oncological diagnosis. All the patients
were subject to regular follow-up, which included clin-
ical examination and imaging tests.
Definitions
Primary tumours were defined as lesions originating in
the adrenal gland. The potential risk of malignancy of
the pheochromocytomas was evaluated with the Pheo-
chromocytoma of Adrenal Gland Scaled Score (PASS);
in postoperative pathological examination pheochromo-
cytomas with a PASS score of 6 or higher were defined
as potentially malignant [8]. Metastasis was defined as
an adrenal tumour, discovered during follow-up diagnos-
tic imaging, in patients with history of cancer in a differ-
ent location, with a pathological diagnosis convergent
with that of the later removed adrenal tumour.
The surgical procedure was described as R0 resection
(macroscopically and microscopically radical), R1 resection
(macroscopically radical, microscopically not radical – if
the operative margin was smaller than 3 mm or when the
pathologist was unable to definitively evaluate the radical-
ity of the procedure in the report) or R2 resection (a pro-
cedure macroscopically and microscopically not radical or
an intraoperative perforation of the tumour capsule).
The analysed measures were: conversion rate, intra- and
postoperative complications, intraoperative blood loss and
R0 resection rate. Survival was estimated using the
Kaplan-Meier method. The study was conducted accord-
ing to the Report of the ISPOR Task Force on Retros-
pective Databases [9]. All procedures were followed in
accordance with the ethical standards of the responsible
committee on human experimentation (institutional and
national) and the Helsinki Declaration of 1975, as revised
in 2008. The independent ethics committee of the Jagiello-
nian University, Krakow (KBET/45/B/2010) approved the
study. Informed consent was obtained from all patients
before surgery.
During the study period 495 patients were submitted
to laparoscopy. In 60/495 (12.1 %) patients a significant
suspicion of malignancy was established before surgery
through clinical evaluation and diagnostic imaging. In
this group, 30 (50 %) patients were operated due to sus-
pected adrenal metastasis. The malignant character of
the tumour was confirmed through pathological examin-
ation in 35 (58.3 %) out of the 60 patients. Moreover, in
17 (3.9 %) more patients, in whom the preoperative
imaging did not clearly indicate malignancy, it was con-
firmed in the postoperative pathological examination.
(Table 1). Further analysis included 52 patients with a
postoperative diagnosis of malignancy or potential ma-
lignancy. This group included 23 women and 29 men.
The mean age in the studied group was 57 years (with a
range of 19–87 years). The demographic characteristics
of this group are presented in Table 2.
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Fourteen (26.9 %) patients had a primary malignant
adrenal tumour, 22 (42.3 %) adrenal metastasis and in 16
(30.8 %) pheochromocytoma with the malignant pheno-
type. Out of 14 primary malignant lesions, 3 (21.4 %)
were hormonally active (2x glucocorticoid-secreting and
1 aldosterone-secreting). None of the metastases were
hormonally active, whereas in 15/16 (93.7 %) cases of
pheochromocytoma, catecholamines hypersecretion was
confirmed preoperatively. Table 3 presents the patho-
logical types of the removed lesions.
Results
In 47 (90.3 %) of the patients, the tumour was removed
using the laparoscopic technique. Conversion was neces-
sary in 5 (9.7 %) of the patients. The reasons for conver-
sion are presented in Table 4.
Mean blood loss was 220 ml (10–1500 ml). In 3 pa-
tients blood transfusions were necessary. Complications
occurred in a total of 6 patients (11.5 %) and included
hepatic parenchymal injury, damage to the splenic vein
(not requiring splenectomy), aortic injury (during the
open phase after conversion), pleural effusion and surgi-
cal site infection in 2 patients. None of the patients re-
quired reoperation. One female patient with multiple
co-morbidities (ASA IV) with a pheochromocytoma that
was additionally secreting corticosteroids required trans-
fer to the intensive care unit on the day of surgery due
to cardiopulmonary decompensation. This patient died
on the 6th postoperative day.
Pathologic results confirmed R0 resection in 41
(78.8 %) of the patients and R1 resection in 9 (17.3 %)
of the patients. In 2 (3.9 %) of the patients R2 resection
was performed. Postoperative mitotane therapy was
applied in all patients with ACC and in 8 patients with
metastasis, adjuvant chemotherapy was introduced ac-
cording to the type of cancer. Patients with pheo-
chromocytoma were not subject to adjuvant treatment.
The mean follow-up time was 32.9 months (median:
24 months). One patient who died in the hospital was
excluded from the analysis of follow-up time and long-
term survival. The Kaplan-Meier survival curves for the
entire group as well as for each tumour type are pre-
sented in Figs. 1 and 2.
Discussion
According to most, if not all guidelines, any suspected
adrenal malignancy is an indication for open adrenalec-
tomy and this recommendation is very rarely questioned
[10, 11]. Nowadays, most adrenalectomies worldwide are
performed laparoscopically. Analyzing indications it be-
comes obvious that, at least in some cases, the above-
mentioned rule is silently and unnoticeably violated.
Indeed, the true indication for the removal of incidenta-
lomas results from concern that the early stages of
cancer may have been overlooked [12]. All guidelines
raise the issue of selection of cases where the risk of
malignancy is high enough to justify adrenalectomy in
hormonally silent tumours. As a natural consequence
the firm adherence to this principle “always open surgery
in any suspicion of malignant tumour” automatically
implies that all incidentalomas should be operated clas-
sically. Meanwhile, looking at most series of minimally
invasive adrenalectomy, at least half of all patients oper-
ated on for incidentalomas and internal contradiction
using this approach is never questioned [13–15]. Thus,
we believe that the opinion about open surgery for non-
secreting tumours should be revised. In our series the
risk of malignancy in unsuspected incidentalomas was
3.9 %. Similar data can be found elsewhere [15, 16]. This
implies that removing every incidentaloma in this way
would be unnecessary overtreatment in almost all cases.
Even though it may sound controversial, we believe that
the same is true for cases with a higher risk of malignancy.
The precise preoperative diagnostics of the potentially
malignant character of pheochromocytomas remains an
important challenge. It is generally accepted that in over
10 % of cases they can exhibit a malignant phenotype [17].
Only metastases observed at diagnosis or infiltration of
surrounding organs observed at diagnosis are certain
features of malignancy. This is, however, very rare. In most
cases, they develop postoperatively in the follow-up
period. Unfortunately, if there are no metastases, it is not
possible to precisely evaluate the degree of malignancy
based on biochemical and imaging tests [18, 19]. Patho-
logical examination may also prove inconclusive. The
most frequently employed scale for estimating the risk is
PASS (Pheochromocytoma of the Adrenal Gland Scaled
Score), proposed by Thompson in 2002 [20]. Though
Table 1 Preoperative and postoperative character of the
removed adrenal tumours
Preoperative tumour with
suspected malignancy n = 60
Postoperative
benign tumour
n = 25 (41.7 %)
Postoperative
malignant tumour
n = 35 (58.3 %)
Preoperative tumour without
suspicion of malignancy n = 435
Postoperative
malignant tumour
n = 17 (3.9 %)
Postoperative
benign tumour
n = 418 (96.1 %)
Table 2 Demographic characteristics of the study group
Number of patients 52
Number of women 23 (44.2 %)
Number of men 29 (55.8 %)
Mean age 57 years (19–87 years)
Mean tumour size 58 mm (18–160 mm)
Left/right side 21/31
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highly popular, its effectiveness for discovering malig-
nant pheochromocytomas is highly debatable [21, 22].
Thompson has suggested that tumours with a PASS ≥ 6
were biologically more aggressive than tumours with a
PASS <4. Meanwhile, Strong has observed that all patients
in whom a progression of the disease was observed had
tumours with a PASS over 6 [8]. This criterion was
adapted for the purposes of our analysis. However, based
on our observations, it appears that if there are no metas-
tases during the operation, the risk of relapse is very low,
since none of our patients relapsed. To some extent, this
confirms the opinions that the PASS, despite being the
most frequently used tool, does not allow for precisely
predicting the postoperative course after the adrenalec-
tomy for pheochromocytoma. An important conclusion
arising from the analysis of our results is that laparoscopic
adrenalectomy is a safe procedure in cases of pheochro-
mocytoma considered as potentially malignant neoplasms.
Additionally, if the pathological examination shows char-
acteristics that may indicate a malignant phenotype, the
procedure does not have a negative impact on the patient's
outcomes, as compared to open surgery. Other authors
also consider laparoscopic surgery a safe method, and rec-
ommend it as the method of choice, regardless of tumour
size and the preoperative clinical picture, even though the
malignant potential of pheochromocytoma is relatively
high [23–25].
Nowadays, laparoscopic surgery has become a good al-
ternative to open surgery in patients with isolated metas-
tases. Despite certain controversy surrounding attempts
at surgical treatment in patients with advanced stage
cancer, it seems that, taking into account the advantages
of minimally invasive techniques, laparoscopic adrenal-
ectomy is perceived as an effective treatment method in
chosen cases [26–28]. Research including relatively nu-
merous groups of patients shows that such treatment
enables prolonged disease free survival. In Moreno's
study of 317 patients, the survival rate after one, two,
three and five years was 80 %, 61 %, 42 % and 35 %, re-
spectively [26]. Romero Arenas reported similar results
(70 % survival after a year, 44 % after 3 years and 38 %
after 5 years) [27]. Vazquez underlined one more im-
portant aspect – the treatment results depend also on
the type of the primary tumour and thus may differ be-
tween study groups [29]. In our study, the survival rates
for patients with metastases after a year, 2 years and
5 years were 82.4 %, 46.2 % and 40 %, respectively, which
is similar to the results reported by other authors. The
published papers comparing laparoscopic adrenalectomy
with open surgery did not indicate any difference in sur-
vival rate between the methods, though they did note
the obvious advantages of laparoscopy in early postoper-
ative outcomes. All this contributes to a preference for
laparoscopy in patients with metastases to the adrenal
glands [30, 31, 26, 32–35, 29].
Our approach favours laparoscopy in all adrenal gland
tumours, as it clearly emerges from this paper. In our
series, in only 67.3 % (35/52) of the adrenal tumours
with histologically confirmed malignant character was
there significant suspicion of malignancy preoperatively.
Furthermore, out of this group, 85.7 % (30/35) were
patients with metastases. In other cases (17, 32.6 %) the
character of the malignant or potentially malignant
tumour was determined only postoperatively. Such a
context calls into question the legitimacy of recommen-
dations, which favour open techniques in these cases as
Table 3 Pathological types of the removed lesions
Mean size Histological type n (%) n (%)
Primary malignant adrenal tumour 74.9 mm (23 – 160 mm) Adrenocortical cancer (ACC) 12 (23.1 %) 14 (26.9 %)
Primitive neuroectodermal tumour (PNET) 1 (1.9 %)
Lymphoma 1 (1.9 %)
Metastasis 46.9 mm (18–80 mm) Renal cell carcinoma 11 (21.2 %) 22 (42.3 %)
Non-small cell lung cancer 7 (13.5 %)
Colonic adenocarcinoma 2 (3.8 %)
Hepatocellular carcinoma 1 (1.9 %)
Sarcoma 1 (1.9 %)
Malignant pheochromocytoma 59.8 mm (23–120 mm) Malignant pheochromocytoma (PASS≥ 6) 16 (30.8 %) 16 (30.8 %)
All 58 mm (18–160 mm) 52 (100 %) 52 (100 %)
Table 4 Reasons for conversion
Final diagnosis Size (mm) Reason of conversion
Pheochromocytoma 50 Infiltration to the back wall of the
abdominal cavity
ACC 160 Suspicion of tumour capsule injury
Metastasis
(renal cell cancer)
88 Adhesions after a previous surgery
ACC 120 Impossibility of safe laparoscopic
dissection
Pheochromocytoma 120 uncontrolled bleeding
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nearly 1/3 of malignant tumours would be operated
laparoscopically anyway. Some authors argue that in the
case of primary adrenal malignancy, the preferred tech-
nique should be open surgery. They argue that local
recurrence and peritoneal metastases occur sooner in
patients who undergo laparoscopic adrenalectomy and
positive resection margins are more frequently positive
[36–39]. Others believe that the surgical approach does
not have such a significant impact [7, 40, 41]. It seems
that the role of the operative technique is the key ques-
tion in this debate. In our opinion, laparoscopy differs
only in that it involves a different access to the operated
area. It allows for performing exactly the same operation
meeting all the oncological principles (including in
multi-organ resection and full lymphadenectomy) as
long as it is performed by a skilled and experienced
surgeon. We are certain that this aspect has more influ-
ence on the outcomes than the type of access itself.
Moreover, in tumours located elsewhere (for instance,
colon cancer), laparoscopy is an equal alternative to
open operations, while giving the well-known advantages
of reduced surgical trauma [42, 43]. It is even more so
from a practical point of view, since a return to more
frequent application of open surgery seems impossible,
and often stands in contradiction to the expectations of
both the patients and surgeons. It seems, however, rea-
sonable that beginning every operation with laparoscopy,
even in cases of larger and potentially malignant
tumours, may be beneficial. It allows for a minimally
invasive assessment of the entire abdominal cavity,
searching for distant metastases and estimating the pos-
sibility of radical resection of the lesion without exposing
the patient to large surgical trauma. Obviously the need
for conversion arises whenever technical difficulties put
into question the oncological quality of the procedure
(dissecting the tumour, which could lead to damaging
the tumour capsule, or doubts as to possible infiltration
of neighbouring organs) [44, 5, 45, 11]. We also do not
support laparoscopic surgery at all costs. Overall, con-
version was necessary for 5 patients, out of which in 3
cases it was for “oncological reasons” (impossibility of
dissecting the tumour, suspicion of capsule rupture). In
the remaining 47 (90.3 %) patients, the procedure was
carried out laparoscopically. The presented R0 resection
rate of 78.8 % is a fully acceptable result, and certainly
comparable, if not better than the results for open
surgery [7, 36, 39]. This suggests that the laparoscopy
allows for the achievement of satisfactory oncological
outcomes. According to our data, the survival rate for
patients with ACC after 1, 2, and 5 years was, re-
spectively, 81.8 %, 70 % and 50 %. These results are
slightly better than in other papers; however, they
need to be interpreted with some caution, given the
small study group size [46, 6]. Another issue is that
we are the high-volume referral centre for adrenal
pathologies and this is a proven factor for better out-
comes [47, 48].
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Our study is not free from limitations. It is a single
centre retrospective study on a small sample, therefore
defining confounders can be difficult and there is a
potential for population bias. All procedures were
performed by the same very experienced laparoscopic
surgeon (>370 laparoscopic adrenalectomies), therefore
the results probably cannot be simply transferred to all
surgical departments.
Conclusions
In summary, we consider that laparoscopic surgery for
malignant or potentially malignant adrenal tumours is
feasible. Safe laparoscopic surgery for any type of pheo-
chromocytoma is a fact; especially that we are not able
to distinguish a malignant from a benign tumour and
even if it turns out to be potentially malignant, the long-
term survival is very good. In patients with metastatic
malignancy, adrenal metastasectomy seems to be a rea-
sonable, less invasive solution allowing for comparable if
not better results. Finally, the biggest concern remains
primary adrenocortical cancer. Our results suggest that
it is impossible to predict its occurrence in incidentalo-
mas. In our opinion, if laparoscopy does not improve the
outcomes, in the hand of an experienced surgeon it
guarantees the possibility of noninferiority. Therefore, it
can be recommended in most tumours. Additionally,
beginning a procedure with laparoscopy allows for a
precise, minimally invasive evaluation of the tumour
stage. The key element in surgery for any suspected
malignancy is not the surgical access itself but the
proper technique in accordance with the principles of
oncological surgery.
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